시장보고서
상품코드
2060262

혈류 감염 검사 시장 분석 및 예측 : 유형, 제품 유형, 서비스, 기술, 용도, 기기, 프로세스, 최종 사용자, 솔루션(-2035년)

Bloodstream Infection Testing Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Device, Process, End User, Solutions

발행일: | 리서치사: 구분자 Global Insight Services | 페이지 정보: 영문 350 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    



가격
PDF & Excel (Single User License) help
PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF, Excel 이용 범위와 동일합니다.
US $ 4,750 금액 안내 화살표 ₩ 7,409,000
PDF & Excel (Site License) help
PDF, Excel 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다.
US $ 5,750 금액 안내 화살표 ₩ 8,969,000
PDF & Excel (Enterprise License) help
PDF, Excel 보고서를 동일 기업의 전 세계 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF, Excel 이용 범위와 동일합니다.
US $ 6,750 금액 안내 화살표 ₩ 10,529,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 혈류 감염 검사 시장은 2025년 42억 달러에서 2035년까지 78억 달러로 성장하여 CAGR은 6.2%를 나타낼 것으로 예측됩니다. 혈류 감염 검사 시장은 중간 정도의 통합이 진행된 구조를 특징으로 하며, 주요 부문인 분자진단과 미생물학 검사가 각각 시장 점유율의 약 45%와 30%를 차지하고 있습니다. 주요 제품 카테고리에는 장비, 시약, 소프트웨어 솔루션이 포함되며, 주로 병원, 진단실험실, 연구소에서 사용됩니다. 시장 규모는 신속하고 정확한 감염병 검출에 대한 수요 증가를 반영하여, 연간 실시되는 진단 검사 건수 증가에 힘입어 성장하고 있습니다.

용도 부문에서는 세균성 감염증 검사가 주류를 이루고 있으며, 이는 세균성 혈류 감염의 높은 유병률과 신속한 진단에 대한 절실한 수요를 반영하고 있습니다. 진균 및 바이러스 감염증 검사도 중요한 위치를 차지하고 있으며, 이에 대한 인식 제고와 발생률 증가가 수요를 견인하고 있습니다. 병원 및 진료소가 주요 이용처이며, 패혈증 발생률 감소와 치료 성과 향상에 주력하고 있습니다. 맞춤형 의료의 동향은 더욱 정밀하고 효율적인 진단 검사의 개발에 영향을 미치고 있습니다.

최종 사용자 부문에서는 환자 관리를 효과적으로 수행하기 위한 정확하고 신속한 진단 수요에 힘입어, 병원과 진단실험실이 혈류 감염 검사 솔루션의 주요 이용자가 되고 있습니다. 병원 내 감염 발생률 증가가 이 부문의 주요 성장 동력이 되고 있습니다. 재택의료 부문은 원격 모니터링 및 검사를 가능하게 하는 기술의 발전에 힘입어, 재택의료 서비스에 대한 수요 증가에 부응하는 형태로 성장하고 있습니다.

지역별 개요

북미는 고도로 발달된 의료 인프라와 감염 관리 및 환자 안전에 대한 높은 중시 덕분에 혈류 감염 검사 시장을 주도하고 있습니다. 이 지역은 분자 검사 및 자동 혈액 배양 시스템과 같은 첨단 진단 기술을 조기에 도입한 덕분에 감염병을 신속하고 정확하게 검출할 수 있게 되었습니다. 높은 의료비 지출, 유리한 환급 정책, 그리고 주요 기업들의 강력한 입지가 시장 확산을 더욱 촉진하고 있습니다. 또한, 병원 내 감염 및 패혈증 사례 증가로 인해 효율적인 검사 솔루션에 대한 수요가 높아지고 있으며, 이는 세계 시장에서 해당 지역의 선도적 입지를 더욱 공고히 하고 있습니다.

아시아태평양은 의료 인프라 확충과 감염병 부담 증가를 배경으로, 혈류 감염 검사 시장에서 가장 빠르게 성장하고 있는 지역입니다. 진단실험실에 대한 투자 확대, 질병 조기 발견에 대한 인식 제고, 그리고 의료 서비스 접근성 개선이 첨단 검사 솔루션의 도입을 가속화하고 있습니다. 또한, 이 지역은 막대한 환자 수와 검사 시스템의 지속적인 현대화라는 혜택도 누리고 있습니다. 또한, 감염 관리 강화와 선별 검사 프로그램 확충에 중점을 둔 정부의 이니셔티브이 시장 성장을 뒷받침하고 있으며, 아시아태평양은 혈류 감염 검사 분야의 주요 성장 거점으로서의 입지를 확고히 하고 있습니다.

주요 동향 및 촉진요인

패혈증 및 병원 내 감염 발생률 증가:

혈류 감염 검사 시장은 주로 전 세계 의료 시스템에서 패혈증, 균혈증, 병원 내 감염의 발생률 증가에 힘입어 성장하고 있습니다. 침습적 시술 증가, 고령화, 그리고 만성 질환 유병률의 상승으로 인해 혈류 감염에 대한 취약성이 현저히 높아지고 있습니다. 또한, 항생제 내성의 확산으로 인해 효과적인 치료 방침을 결정하기 위해서는 신속하고 정확한 병원체 검출이 필수적입니다. 의료 제공업체들은 조기 발견률 향상, 사망률 감소 및 환자 예후 개선을 도모하기 위해 PCR 기반 검사나 자동 혈액 배양 시스템과 같은 첨단 진단 도구를 점점 더 많이 도입하고 있으며, 이에 따라 시장 성장이 가속화되고 있습니다.

신속 분자진단 및 현장 진단 검사의 확대:

시장에서의 주요 기회는 신속 분자진단 및 현장 진단(POC) 검사 솔루션의 도입 확대에 있습니다. PCR, 차세대 염기서열 분석, 자동 식별 시스템 등의 기술 혁신으로 인해 감염증 검출에 소요되는 시간이 대폭 단축되어, 임상 판단을 신속하게 내릴 수 있게 되었습니다. 응급실이나 중환자실(ICU)에서 분산형 검사에 대한 수요가 증가하는 것도 도입을 더욱 촉진하고 있습니다. 또한, 주요 기업들의 기술 발전과 지속적인 신제품 출시로 인해, 더욱 정확하고 효율적인 검사 플랫폼을 활용할 수 있는 기회가 확대되고 있습니다. 이러한 추세는 특히 집중 치료나 의료 부담이 큰 의료 현장에서 시장 확대를 위한 큰 기회를 창출하고 있습니다.

목차

제1장 주요 요약

제2장 시장 하이라이트

제3장 시장 역학

제4장 부문 분석

제5장 지역별 분석

제6장 시장 전략

제7장 경쟁 정보

제8장 기업 개요

제9장 당사에 대해

JHS 26.06.19

The global Bloodstream Infection Testing Market is projected to grow from $4.2 billion in 2025 to $7.8 billion by 2035, at a compound annual growth rate (CAGR) of 6.2%. The Bloodstream Infection Testing Market is characterized by its moderately consolidated structure, with the leading segments being molecular diagnostics and microbiology testing, holding approximately 45% and 30% of the market share, respectively. Key product categories include instruments, reagents, and software solutions, with applications primarily in hospitals, diagnostic laboratories, and research institutes. The market volume is driven by the increasing number of diagnostic tests conducted annually, reflecting a growing demand for rapid and accurate infection detection.

The Application segment is dominated by bacterial infection testing, reflecting the high prevalence of bacterial bloodstream infections and the critical need for timely diagnosis. Fungal and viral infection testing are also significant, with increasing awareness and incidence rates driving demand. Hospitals and clinics are the primary users, focusing on reducing the incidence of sepsis and improving treatment outcomes. The trend towards personalized medicine is influencing the development of more targeted and efficient diagnostic tests.

Market Segmentation
TypeConventional Testing, Rapid Testing, Others
ProductInstruments, Reagents & Kits, Software, Others
ServicesLaboratory Services, Consulting Services, Others
TechnologyPCR, Microarray, Immunoassay, Mass Spectrometry, Next-Generation Sequencing, Others
ApplicationSepsis, Bacteremia, Fungemia, Others
DeviceAutomated Systems, Semi-Automated Systems, Manual Systems, Others
ProcessSample Collection, Sample Preparation, Detection, Others
End UserHospitals, Diagnostic Laboratories, Academic & Research Institutes, Others
SolutionsIn-House Solutions, Outsourced Solutions, Others

In the End User segment, hospitals and diagnostic laboratories are the primary consumers of bloodstream infection testing solutions, driven by the need for accurate and rapid diagnosis to manage patient care effectively. The rising incidence of hospital-acquired infections is a key driver for this segment. The home healthcare segment is emerging, supported by technological advancements that enable remote monitoring and testing, catering to the growing demand for at-home medical services.

Geographical Overview

North America dominates the bloodstream infection testing market due to its highly advanced healthcare infrastructure and strong focus on infection control and patient safety. The region benefits from early adoption of advanced diagnostic technologies such as molecular testing and automated blood culture systems, enabling rapid and accurate detection of infections. High healthcare spending, favorable reimbursement policies, and strong presence of leading diagnostic companies further support widespread adoption. In addition, increasing cases of hospital-acquired infections and sepsis have led to greater demand for efficient testing solutions, reinforcing the region's leadership in the global market.

Asia Pacific is the fastest-growing region in the bloodstream infection testing market, driven by expanding healthcare infrastructure and rising burden of infectious diseases. Increasing investments in diagnostic laboratories, growing awareness about early disease detection, and improving access to healthcare services are accelerating adoption of advanced testing solutions. The region also benefits from large patient populations and ongoing modernization of laboratory systems. Additionally, government initiatives focused on strengthening infection control and increasing screening programs are supporting market growth, positioning Asia Pacific as a key expansion hub for bloodstream infection diagnostics.

Key Trends and Drivers

Rising Incidence of Sepsis and Hospital-Acquired Infections:

The bloodstream infection testing market is primarily driven by the increasing incidence of sepsis, bacteremia, and hospital-acquired infections across global healthcare systems. Rising use of invasive procedures, aging populations, and higher prevalence of chronic diseases have significantly increased vulnerability to bloodstream infections. Additionally, growing antimicrobial resistance is making rapid and accurate pathogen detection essential for effective treatment decisions. Healthcare providers are increasingly adopting advanced diagnostic tools such as PCR-based assays and automated blood culture systems to improve early detection, reduce mortality rates, and enhance patient outcomes, thereby accelerating market growth.

Expansion of Rapid Molecular Diagnostics and Point-of-Care Testing:

A major opportunity in the market lies in the growing adoption of rapid molecular diagnostics and point-of-care (POC) testing solutions. Innovations such as PCR, next-generation sequencing, and automated identification systems are significantly reducing turnaround time for infection detection, enabling faster clinical decision-making. Increasing demand for decentralized testing in emergency departments and intensive care units is further supporting adoption. In addition, technological advancements and ongoing product launches by key players are expanding the availability of more accurate and efficient testing platforms. These developments are creating strong opportunities for market expansion, especially in critical care and high-burden healthcare settings.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Device
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Conventional Testing
    • 4.1.2 Rapid Testing
    • 4.1.3 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Instruments
    • 4.2.2 Reagents & Kits
    • 4.2.3 Software
    • 4.2.4 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Laboratory Services
    • 4.3.2 Consulting Services
    • 4.3.3 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 PCR
    • 4.4.2 Microarray
    • 4.4.3 Immunoassay
    • 4.4.4 Mass Spectrometry
    • 4.4.5 Next-Generation Sequencing
    • 4.4.6 Others
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Sepsis
    • 4.5.2 Bacteremia
    • 4.5.3 Fungemia
    • 4.5.4 Others
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Diagnostic Laboratories
    • 4.6.3 Academic & Research Institutes
    • 4.6.4 Others
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Sample Collection
    • 4.7.2 Sample Preparation
    • 4.7.3 Detection
    • 4.7.4 Others
  • 4.8 Market Size & Forecast by Device (2020-2035)
    • 4.8.1 Automated Systems
    • 4.8.2 Semi-Automated Systems
    • 4.8.3 Manual Systems
    • 4.8.4 Others
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 In-House Solutions
    • 4.9.2 Outsourced Solutions
    • 4.9.3 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Device
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Device
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Device
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Device
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Device
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Device
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Device
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Device
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Device
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Device
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Device
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Device
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Device
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Device
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Device
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Device
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Device
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Device
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Device
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Device
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Device
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Device
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Device
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Device
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Roche Diagnostics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 bioMerieux
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Becton Dickinson
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Thermo Fisher Scientific
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Abbott Laboratories
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Siemens Healthineers
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Danaher Corporation
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Qiagen
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Hologic
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Luminex Corporation
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Bio-Rad Laboratories
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Cepheid
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Grifols
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Meridian Bioscience
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 GenMark Diagnostics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 T2 Biosystems
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Accelerate Diagnostics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 F. Hoffmann-La Roche
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Bruker Corporation
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Illumina
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
kr-info@giikorea.co.kr
문의하기